Billeaud Capital Management Inc. reduced its stake in Becton Dickinson and Co (NYSE:BDX) by 8.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,968 shares of the medical instruments supplier’s stock after selling 173 shares during the quarter. Becton Dickinson and accounts for approximately 0.2% of Billeaud Capital Management Inc.’s holdings, making the stock its 26th largest position. Billeaud Capital Management Inc.’s holdings in Becton Dickinson and were worth $443,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of BDX. Fundsmith Equity Fund L.P. bought a new stake in Becton Dickinson and during the second quarter valued at about $894,775,000. Morgan Stanley raised its holdings in Becton Dickinson and by 133.0% during the third quarter. Morgan Stanley now owns 2,771,269 shares of the medical instruments supplier’s stock valued at $723,303,000 after acquiring an additional 1,581,829 shares during the period. FMR LLC grew its position in shares of Becton Dickinson and by 8.0% during the third quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock valued at $4,529,401,000 after purchasing an additional 1,286,579 shares in the last quarter. Cornerstone Wealth Management LLC grew its position in shares of Becton Dickinson and by 233.6% during the third quarter. Cornerstone Wealth Management LLC now owns 647,786 shares of the medical instruments supplier’s stock valued at $3,286,000 after purchasing an additional 453,623 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Becton Dickinson and by 1.3% during the third quarter. Vanguard Group Inc. now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after purchasing an additional 283,433 shares in the last quarter. 83.77% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently weighed in on BDX shares. Morgan Stanley raised their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research report on Thursday, October 4th. Barclays initiated coverage on Becton Dickinson and in a research report on Monday, October 15th. They issued an “equal weight” rating and a $278.00 price target for the company. Piper Jaffray Companies decreased their price objective on shares of Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, November 6th. Wells Fargo & Co decreased their price objective on shares of Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, November 7th. Finally, KeyCorp raised their price objective on shares of Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a research note on Thursday, November 8th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $251.85.
NYSE BDX traded down $0.58 during trading on Friday, hitting $228.87. The stock had a trading volume of 937,300 shares, compared to its average volume of 1,349,775. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.03 and a quick ratio of 0.69. The company has a market cap of $61.02 billion, a P/E ratio of 20.79, a PEG ratio of 1.63 and a beta of 1.21. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $265.87.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.88%. The firm had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the previous year, the firm posted $2.40 earnings per share. The company’s revenue was up 39.0% on a year-over-year basis. As a group, equities research analysts expect that Becton Dickinson and Co will post 12.11 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 31st. Investors of record on Monday, December 10th were paid a $0.77 dividend. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Friday, December 7th. This represents a $3.08 dividend on an annualized basis and a yield of 1.35%. Becton Dickinson and’s payout ratio is 27.97%.
In other Becton Dickinson and news, EVP James W. Borzi sold 5,887 shares of Becton Dickinson and stock in a transaction on Friday, November 30th. The shares were sold at an average price of $252.37, for a total value of $1,485,702.19. Following the transaction, the executive vice president now directly owns 6,013 shares of the company’s stock, valued at $1,517,500.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vincent A. Forlenza sold 16,866 shares of Becton Dickinson and stock in a transaction on Tuesday, November 13th. The stock was sold at an average price of $237.61, for a total transaction of $4,007,530.26. The disclosure for this sale can be found here. Insiders sold 81,795 shares of company stock valued at $19,571,318 in the last three months. 0.12% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Billeaud Capital Management Inc. Sells 173 Shares of Becton Dickinson and Co (BDX)” was originally published by Macon Daily and is the property of of Macon Daily. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://macondaily.com/2019/01/11/billeaud-capital-management-inc-sells-173-shares-of-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Cost of Equity For A Business, Investors
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.